Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.

Wiersma TG, Dahele M, Verbakel WF, van de Ven PM, de Haan PF, Smit EF, van Reij EJ, Slotman BJ, Senan S.

Lung Cancer. 2013 Apr;80(1):62-7. doi: 10.1016/j.lungcan.2013.01.006. Epub 2013 Jan 26.

PMID:
23357464
2.

Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.

Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):985-91. doi: 10.1016/j.ijrobp.2010.06.059. Epub 2010 Oct 6.

PMID:
20932684
3.

Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.

Lee VH, Chan WW, Lee EY, Choy TS, Ho PP, Leung DK, Lam KO, Kwong DL, Leung TW, Khong PL.

Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070.

PMID:
24710123
4.

Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.

Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, Smit A, Rikers C, van den Heuvel M.

Clin Lung Cancer. 2013 Sep;14(5):541-8. doi: 10.1016/j.cllc.2013.04.001. Epub 2013 Jul 5.

PMID:
23835165
5.

Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.

Dickhoff C, Hartemink KJ, van de Ven PM, van Reij EJ, Senan S, Paul MA, Smit EF, Dahele M.

Lung Cancer. 2014 Aug;85(2):218-23. doi: 10.1016/j.lungcan.2014.06.005. Epub 2014 Jun 16.

PMID:
24976333
6.

Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.

Lung Cancer. 2015 Jan;87(1):23-7. doi: 10.1016/j.lungcan.2014.10.016. Epub 2014 Nov 6.

PMID:
25468149
7.

Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.

Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.

Clin Lung Cancer. 2013 Jul;14(4):370-5. doi: 10.1016/j.cllc.2012.10.009. Epub 2012 Dec 20.

PMID:
23260389
8.

Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.

Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA.

Lung Cancer. 2013 Oct;82(1):95-102. doi: 10.1016/j.lungcan.2013.07.023. Epub 2013 Aug 6.

PMID:
23973202
9.

Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer.

Zhou M, Li T, Liu Y, Sun C, Li N, Xu Y, Zhu J, Ding Z, Wang Y, Huang M, Peng F, Wang J, Ren L, Lu Y, Gong Y.

BMC Cancer. 2015 Feb 6;15:36. doi: 10.1186/s12885-015-1036-0.

10.

Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.

Topkan E, Parlak C, Selek U.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):697-704. doi: 10.1016/j.ijrobp.2013.07.033. Epub 2013 Sep 10.

PMID:
24035331
11.
12.

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N.

BMC Cancer. 2014 Jan 14;14:18. doi: 10.1186/1471-2407-14-18.

13.

The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.

Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, Kucharczuk JC, Lin L, Rengan R.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):340-7. doi: 10.1016/j.ijrobp.2011.05.070. Epub 2011 Nov 19.

PMID:
22104359
14.

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.

Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH, Cho KH, Han JY, Lee YJ, Yun T, Kim HT, Lee JS.

Radiat Oncol. 2014 Dec 13;9:283. doi: 10.1186/s13014-014-0283-6.

15.

Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.

Ziel E, Hermann G, Sen N, Bonomi P, Liptay MJ, Fidler MJ, Batus M, Warren WH, Chmielewski G, Sher DJ.

J Thorac Oncol. 2015 Oct;10(10):1475-80. doi: 10.1097/JTO.0000000000000639.

16.

Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.

Moreno-Jiménez M, Aristu J, López-Picazo JM, Ramos LI, Gúrpide A, Gómez-Iturriaga A, Valero J, Martínez-Monge R.

Radiother Oncol. 2008 Sep;88(3):342-50. doi: 10.1016/j.radonc.2008.05.019. Epub 2008 Jun 14.

PMID:
18558448
17.

[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].

Wang J, Pang QS, Wang P, Wang J, Wang W.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72. Chinese.

PMID:
18396691
18.

Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy.

Song CH, Pyo H, Moon SH, Kim TH, Kim DW, Cho KH.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):651-8. doi: 10.1016/j.ijrobp.2009.08.068. Epub 2010 Mar 6.

PMID:
20207499
20.

Supplemental Content

Support Center